combacte-magnet News Item


The 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), will take place on 9 – 12 July 2021. This time, ECCMID will be held for the first time online, due to the COVID-19 pandemic.

Last year a record number of COMBACTE abstracts were submitted to the conference, but were not presented as ECCMID was cancelled. This year we are proud to announce that 19 COMBACTE abstracts have been accepted for presentation at the conference: 6 from COMBACTE-NET, 10 from COMBACTE-MAGNET, 1 from COMBACTE-CARE and 2 from COMBACTE-CDI. An overview of these abstracts will follow soon.

We spoke to some of the young scientists active in COMBACTE, and the abstracts they will be presenting during ECCMID 2021. Fien De Winter (University of Antwerp) will be presenting an abstract on COMBACTE-MAGNET WP3A study.

“This is the first time I will be presenting at ECCMID. I was very excited to go to the live event, but understand that this is not possible at this time. Nevertheless, the advantages of an online event are numerous, such as being able to follow everything in the comfort of your own home, reduced travel time and reduced ecological impact.

The work I will be presenting is tightly connected to COMBACTE-MAGNET although not using clinical samples. In this fundamental research, we looked into the consequences of biofilm dispersal in an in vivo murine Pseudomonas aeruginosa pneumonia model. We found that induced dispersed cells lead to higher mortality and dissemination in hematopoietic organs when compared to biofilm cells or uninduced dispersed cells. These data suggest that induced dispersal although decreasing biofilm mass, leads to an increased in vivo virulence, sometimes evolving to cytokine storm and related septic shock”.

You can listen to Fien’s presentation at ECCMID on Friday, 9th of July between 17.15 and 18.15.

About WP3A

Elaborate data analysis of P. aeruginosa among ICU patients. The WP3A study is an analysis of data obtained within ASPIRE-ICU –  a prospective cohort study among intensive-care unit patients in Europe with health-care associated infections attributed to P. aeruginosa.

WP3A systematically assesses the impact of host and pathogen-related factors on the incidence of ICU pneumonia in Europe. It is focused on infections caused by P. aeruginosa, but does not exclude other organisms. Another aim is to identify the patient subgroups that bear a disproportionate disease burden. This contributes to optimizing patient selection for clinical trials.

WP3A study

Dr. Nithya Babu Rajendran Reflects On COMBACTE-MAGNET




PPI: The Advantages Of Involving Patients in Clinical Research